Literature DB >> 21844500

Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation.

Sébastien Salas1, Armelle Dufresne, Binh Bui, Jean-Yves Blay, Philippe Terrier, Dominique Ranchere-Vince, Sylvie Bonvalot, Eberhard Stoeckle, Louis Guillou, Axel Le Cesne, Odile Oberlin, Véronique Brouste, Jean-Michel Coindre.   

Abstract

PURPOSE: Desmoid tumors are mesenchymal fibroblastic/myofibroblastic proliferations with locoregional aggressiveness and high ability to recur after initial treatment. We present the results of the largest series of sporadic desmoid tumors ever published to determine the prognostic factors of these rare tumors. PATIENTS AND METHODS: Four hundred twenty-six patients with a desmoid tumor at diagnosis were included, and the following parameters were studied: age, sex, delay between first symptoms and diagnosis, tumor size, tumor site, previous history of surgery or trauma in the area of the primary tumor, surgical margins, and context of abdominal wall desmoids in women of child-bearing age during or shortly after pregnancy. We performed univariate and multivariate analysis for progression-free survival (PFS).
RESULTS: In univariate analysis, age, tumor size, tumor site, and surgical margins (R2 v R0/R1) had a significant impact on PFS. PFS curves were not significantly different for microscopic assessment of surgical resection quality (R0 v R1). In multivariate analysis, age, tumor size, and tumor site had independent values. Three prognostic groups for PFS were defined on the basis of the number of independent unfavorable prognostic factors (0 or 1, 2, and 3).
CONCLUSION: This study clearly demonstrates that there are different prognostic subgroups of desmoid tumors that could benefit from different therapeutic strategies, including a wait-and-see policy.

Entities:  

Mesh:

Year:  2011        PMID: 21844500     DOI: 10.1200/JCO.2010.33.5489

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  90 in total

1.  Is MR-guided High-intensity Focused Ultrasound a Feasible Treatment Modality for Desmoid Tumors?

Authors:  Raffi S Avedian; Rachelle Bitton; Garry Gold; Kim Butts-Pauly; Pejman Ghanouni
Journal:  Clin Orthop Relat Res       Date:  2016-03       Impact factor: 4.176

2.  Large desmoid-type fibromatosis of the shoulder girdle: operative approach selection and clinic outcome.

Authors:  Fan Tang; Li Min; Rui Yin; Wenli Zhang; Yong Zhou; Yi Luo; Rui Shi; Hong Duan; Chongqi Tu
Journal:  Int Orthop       Date:  2015-01-21       Impact factor: 3.075

3.  Clinical features and treatment outcome of desmoid-type fibromatosis: based on a bone and soft tissue tumor registry in Japan.

Authors:  Yoshihiro Nishida; Akira Kawai; Junya Toguchida; Akira Ogose; Keisuke Ae; Toshiyuki Kunisada; Yoshihiro Matsumoto; Tomoya Matsunobu; Kunihiko Takahashi; Kazuki Nishida; Toshifumi Ozaki
Journal:  Int J Clin Oncol       Date:  2019-07-22       Impact factor: 3.402

4.  Pregnancy does not increase the local recurrence rate after surgical resection of desmoid-type fibromatosis.

Authors:  Justin M M Cates
Journal:  Int J Clin Oncol       Date:  2014-08-16       Impact factor: 3.402

Review 5.  Desmoid-Type Fibromatosis: Who, When, and How to Treat.

Authors:  Javier Martínez Trufero; Isabel Pajares Bernad; Irene Torres Ramón; Jorge Hernando Cubero; Roberto Pazo Cid
Journal:  Curr Treat Options Oncol       Date:  2017-05

6.  Prognostic factors for second recurrence after surgical resection of recurrent desmoid-type fibromatosis.

Authors:  Justin M M Cates
Journal:  Pathol Oncol Res       Date:  2015-04-29       Impact factor: 3.201

7.  A prognostic nomogram for prediction of recurrence in desmoid fibromatosis.

Authors:  Aimeé M Crago; Brian Denton; Sébastien Salas; Armelle Dufresne; James J Mezhir; Meera Hameed; Mithat Gonen; Samuel Singer; Murray F Brennan
Journal:  Ann Surg       Date:  2013-08       Impact factor: 12.969

8.  MRI may be used as a prognostic indicator in patients with extra-abdominal desmoid tumours.

Authors:  Firouzeh Kamali; Wei-Lien Wang; B A Guadagnolo; Patricia S Fox; Valerae O Lewis; Alexander J Lazar; Anthony P Conley; Vinod Ravi; Mohammad Toliyat; Harshad S Ladha; Brian P Hobbs; Behrang Amini
Journal:  Br J Radiol       Date:  2015-11-18       Impact factor: 3.039

9.  Simple resection of truncal desmoid tumors: A case series.

Authors:  Yoshihiro Nishida; Satoshi Tsukushi; Hiroshi Urakawa; Shunsuke Hamada; Eiji Kozawa; Kunihiro Ikuta; Naoki Ishiguro
Journal:  Oncol Lett       Date:  2016-06-28       Impact factor: 2.967

10.  Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children's Oncology Group (COG) phase II study.

Authors:  Stephen X Skapek; James R Anderson; D Ashley Hill; David Henry; Sheri L Spunt; William Meyer; Simon Kao; Fredric A Hoffer; Holcombe E Grier; Douglas S Hawkins; R Beverly Raney
Journal:  Pediatr Blood Cancer       Date:  2012-12-31       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.